Therapeutic Management of COVID-19 Patients: Clinical Manifestation and Limitations.

Fatima, Urooj; Rizvi, Syed Saif A; Raina, Neha; Fatima, Saher; Rahman, Safikur; Kamal, Md Amjad; Hassan, Md Imtaiyaz

Fatima, Urooj; Rizvi, Syed Saif A; Raina, Neha; Fatima, Saher; Rahman, Safikur; Kamal, Md Amjad; Hassan, Md Imtaiyaz.

Afiliação

Fatima U; Department of Botany, Aligarh Muslim University, Aligarh 202002, U.P., India.
Rizvi SSA; Department of Surgery, Brigham, and Women's Hospital, Boston, Massachusetts, United States.
Raina N; Department of Biotechnology, School of Engineering and Technology, Sharda University, Greater Noida, U.P, India.
Fatima S; Department Agricultural Microbiology, Aligarh Muslim University, Aligarh 202002, U.P., India.
Rahman S; Munshi Singh College, BR Ambedkar Bihar University, Muzaffarpur, Bihar 845401, India.
Kamal MA; King Fahd Medical Research Center, King Abdulaziz University, P.O. Box 80216, Jeddah 21589, Saudi Arabia.
Hassan MI; Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, Jamia Nagar New Delhi 110025, India.

Curr Pharm Des ; 27(41): 4223-4231, 2021.

Article em En | MEDLINE | ID: mdl-33238869

Assuntos

Antivirais; COVID-19; Antivirais/uso terapêutico; COVID-19/terapia; Síndrome da Liberação de Citocina; Humanos; Hidroxicloroquina; Imunização Passiva; Pandemias; Fitoterapia; Soroterapia para COVID-19

Palavras-chave

COVID19; Chinese herbal medicine; SARSCoV2; chloroquine; cytokine storm.; hydroxychloroquine; plasma therapy; remdesivir; tocilizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 11_ODS3_cobertura_universal / 2_ODS3 / 4_TD / 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Antivirais / COVID-19 Limite: Humans Idioma: En Revista: Curr Pharm Des Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google